Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use ERLEADA safely and effectively. See full prescribing information for ERLEADA. ERLEADA® (apalutamide) tablets, for oral use Initial U.S. Approval – 2018
Medication labelWhy this: Advisory · dailymed-prescription
ERLEADA is indicated for the treatment of patients with Metastatic castration-sensitive prostate cancer (mCSPC) Non-metastatic castration-resistant prostate cancer (nmCRPC)
- generic_name
- apalutamide
- product_names
- Apalutamide
- ndc
- 59676-600, 59676-604, 59676-600-12, 59676-600-99, 59676-600-56, 59676-604-30, 59676-604-14
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en